Press release
Non Muscle Invasive Bladder Cancer Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Curious about the latest updates in the NMIBC Pipeline? @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the NMIBC Pipeline Report
* On July 06, 2026- Merck Sharp & Dohme LLC initiated a phase 1/2 study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
* On July 02, 2026- Astellas Pharma Global Development Inc. announced a phase 3 study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
* On July 01, 2026- CG Oncology Inc . conducted a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
* On July 01, 2026- Ferring Pharmaceuticals highlighted a phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
* DelveInsight's Non Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Non Muscle Invasive Bladder Cancer treatment.
* The leading Non Muscle Invasive Bladder Cancer Companies such as CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
* Promising Non Muscle Invasive Bladder Cancer Therapies such as PF-06801591, Bacillus Calmette-Guerin, CG0070, Gemcitabine, APL-1202 treatment, Durvalumab, eRapa, Epirubicin Hydrochloride, Cabazitaxel, Gemcitabine, Cisplatin and others.
Want to know which companies are leading innovation in Non-Muscle Invasive Bladder Cancer? @ [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The NMIBC Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The NMIBC Pipeline Report also highlights the unmet needs with respect to the development of Non Muscle Invasive Bladder Cancer.
NMIBC Overview
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer in which the tumor remains confined to the inner lining of the bladder and does not invade the muscular wall. NMIBC includes stages Ta, T1, and carcinoma in situ (CIS), and is characterized by abnormal growth of urothelial cells within the bladder mucosa. Although the disease is generally considered less aggressive than muscle-invasive bladder cancer, it has a strong tendency for recurrence and progression in some patients, making continuous monitoring important.
Non Muscle Invasive Bladder Cancer Emerging Drugs Profile
* Cretostimogene grenadenorepvec: CG Oncology
Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate in and destroy bladder cancer cells while also stimulating anti-tumor immune responses. The therapy is engineered with an E2F-1 promoter to target tumor cells with altered Rb-E2F pathways and includes the GM-CSF gene to enhance immune activation. Viral replication causes tumor cell lysis and releases tumor antigens and GM-CSF, helping trigger a sustained immune response against bladder cancer. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.
* FGFR3 (TYRA-300): Tyra Biosciences, Inc.
FGFR3 (TYRA-300) is Tyra Biosciences' lead precision medicine program stemming from its in-house SNAP platform. TYRA-300 is an investigational oral FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia, including achondroplasia and hypochondroplasia. In oncology, TYRA-300 is being evaluated in metastatic urothelial cancer (mUC) and intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.
* MK-3120: Merck & Co., Inc.
MK-3120 is an investigational therapy for bladder cancer, including non-muscle invasive bladder cancer (NMIBC). MK-3120 is a Nectin-4-targeting antibody-drug conjugate (ADC) that carries a topoisomerase I (topo I) inhibitor payload. The drug is designed to specifically bind to Nectin-4, a protein highly expressed on bladder cancer cells. After binding to the tumor cell, the ADC is internalized and releases its topo I inhibitor payload inside the cancer cell, leading to DNA damage, disruption of DNA replication, and ultimately cancer cell death. By selectively targeting Nectin-4-expressing tumor cells, MK-3120 aims to deliver potent anti-cancer activity while limiting exposure to normal tissues. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.
* AU-011: Aura Biosciences
AU-011 is a first-in-class virus-like drug conjugate (VDC) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC). The therapy is designed to selectively target and destroy cancer cells while sparing healthy tissue. AU-011 binds to heparan sulfate proteoglycans (HSPGs), which are overexpressed on bladder cancer cells, allowing selective tumor targeting. After binding to the tumor cells, the drug is activated by light, leading to rapid disruption of the cancer cell membrane and acute tumor cell death. This process also promotes immunogenic cell death, releasing tumor antigens that may stimulate a systemic anti-tumor immune response and generate longer-term immunity against the cancer. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Non Muscle Invasive Bladder Cancer.
NMIBC Market Drivers
* Increasing NMIBC Prevalence
* Advancements in Bladder Cancer Treatment
NMIBC Market Barriers
* Increasing use of Biologics and Targeted Therapies
* High Cost associated with the disease
The Non Muscle Invasive Bladder Cancer Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.
* Non Muscle Invasive Bladder Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.
If you're tracking ongoing NMIBC clinical trials, this press release is a must-read @ [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Non Muscle Invasive Bladder Cancer Companies
CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
From emerging drug candidates to competitive intelligence, the NMIBC Pipeline Report covers it all @ [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the NMIBC Pipeline Report
* Coverage- Global
* NMIBC Companies- CG Oncology, Janssen Research & Development, LLC, Tyra Biosciences, Inc, UroGen Pharma Ltd., Prokarium Ltd, Protara Therapeutics, ImmVira Pharma Co. Ltd, Trigone Pharma Ltd., Hoffmann-La Roche, Aura Biosciences, enGene Holdings Inc., Atonco Pharma and others.
* NMIBC Therapies- PF-06801591, Bacillus Calmette-Guerin, CG0070, Gemcitabine, APL-1202 treatment, Durvalumab, eRapa, Epirubicin Hydrochloride, Cabazitaxel, Gemcitabine, Cisplatin and others.
* NMIBC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NMIBC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what's next for the NMIBC treatment landscape in this detailed analysis @ [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Non Muscle Invasive Bladder Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non Muscle Invasive Bladder Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Cretostimogene grenadenorepvec: CG Oncology
* Mid Stage Products (Phase II)
* TYRA-300: Tyra Biosciences, Inc
* Early Stage Products (Phase I)
* UGN-301: UroGen Pharma Ltd.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Non Muscle Invasive Bladder Cancer Key Companies
* Non Muscle Invasive Bladder Cancer Key Products
* Non Muscle Invasive Bladder Cancer- Unmet Needs
* Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
* Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
* Non Muscle Invasive Bladder Cancer Analyst Views
* Non Muscle Invasive Bladder Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-muscle-invasive-bladder-cancer-pipeline-gains-momentum-20-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non Muscle Invasive Bladder Cancer Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight here
News-ID: 4571058 • Views: …
More Releases from ABNewswire
Kieran J. Woll Redefines Modern Espionage Fiction With a Thriller That Asks What …
Kieran Woll Creative Works LLC unveils a sophisticated espionage narrative that challenges the conventions of the genre by embedding its threat not in a foreign government or rogue state but in the invisible architecture of daily life. The story follows Drake, Voss, and Raven as they confront a network designed to be undetectable and indestructible.
In an era when readers increasingly seek fiction that reflects the genuine complexities of the modern…
Craft Pilot Targets Three High-Growth Markets With Science-Backed Cognitive Well …
Craft Pilot is strategically expanding into the neurodivergent, gerontology, and corporate wellness sectors with products designed to engage the brain through tactile interaction and purposeful cognitive challenges. The company's science-informed approach is attracting growing interest from consumers and organizations seeking practical mental wellness solutions.
The conversation around wellness has evolved dramatically over the past decade. What was once dominated by gym memberships and dietary supplements now encompasses mental health, mindfulness, and…
First-Time Entrepreneur Turns Lifelong Coffee Passion Into Grateful Coffee, a Ne …
A lifelong coffee enthusiast has channeled personal passion into a new venture, launching Grateful Coffee as an online destination for quality-driven coffee lovers. The brand focuses on offering diverse, great-tasting coffee varieties and building a loyal customer base through authentic dedication to the craft.
Behind every memorable brand there is a story, and for Grateful Coffee, that story begins with a first-time entrepreneur who decided that a lifelong love of coffee…
Solar Heroes Helps Singapore Homes and Businesses Beat the Heat and Slash Coolin …
As energy prices climb and the tropical sun grows more punishing, the Singapore based supplier and installer turns attention to its lineup of high performance films that reject up to 99.9 percent of UV rays and up to 62 percent of total solar energy, with pricing that starts at just S$4.80 per square foot.
SINGAPORE - July 10, 2026 - Living and working in Singapore means living with the sun. It…
More Releases for Bladder
Rising Prevalence Of Pediatric Bladder Disorders Fuels Growth In The Pediatric B …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Pediatric Bladder Treatment Industry Market Size Be by 2025?
The market dedicated to pediatric bladder treatment has experienced consistent expansion lately, projected to escalate from a value of $3.54 billion in 2024 up to $3.72 billion in 2025, reflecting a compound annual growth rate (CAGR) of…
Rising Prevalence Of Pediatric Bladder Disorders Fuels Growth In The Pediatric B …
The Pediatric Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Pediatric Bladder Treatment Market?
The market size for pediatric bladder treatment has been expanding significantly in the past few years. The anticipated rise is from $3.54 billion…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Transforming the Pediatric Bladder Treatment Market in 2025: Rising Prevalence O …
What Is the Expected Size and Growth Rate of the Pediatric Bladder Treatment Market?
The pediatric bladder treatment market has grown steadily in recent years. It will increase from $3.54 billion in 2024 to $3.73 billion in 2025, at a CAGR of 5.1%. The growth is due to the prevalence of pediatric bladder conditions, growing awareness of such conditions, improved access to healthcare for children, and rising disposable incomes.
The pediatric bladder…
diaphragm accumulator, bladder accumulator ,ball valve, bladder
Siken Hydraulics Inc. has a team of industry experts with experiences over 20 years ,who are always willing to serve the clients all the time. We could design and offer our hydraulic accumulator, pulsation dampeners, compensators according to different standards such as ASME, CE/PED etc.to meet our customers' diverse needs for our products.
We are providing the piston accumumulator from 0.1L to 500L and operating pressures up to 20,000…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
